The same tendency was present in the extracellular super oxide dismutase (ecSOD) activity in the COVID-19 patients in comparison with healthy subjects (p < 0.001) after the treatment with MT (p = 0.04, Figure 3B). This evidence concerns the gene SOD3 and COVID-19.